Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Semin Oncol. 2010 Apr;37(2):102-9. doi: 10.1053/j.seminoncol.2010.03.013.
Hepatic resection remains the only curative option for the majority of patients with hepatocellular carcinoma (HCC) who do not meet criteria for transplantation or local ablative options. As the majority of patients with HCC also have underlying chronic liver disease and cirrhosis, post-hepatectomy complications can be significant, and in some prohibitive. The technique of portal vein embolization (PVE) has evolved to increase the candidacy of patients for major hepatectomy, as well as improve postoperative outcomes and safety. This review will focus on PVE and discuss our institution's experience with uses and limitations of this technique for HCC.
肝切除术仍然是大多数不符合移植或局部消融治疗标准的肝细胞癌 (HCC) 患者的唯一治愈选择。由于大多数 HCC 患者还存在潜在的慢性肝病和肝硬化,肝切除术后并发症可能很严重,在某些情况下甚至是禁忌的。门静脉栓塞术 (PVE) 的技术已经发展到可以增加患者接受大肝切除术的资格,同时改善术后结果和安全性。本文将重点讨论 PVE,并讨论我们机构在 HCC 中使用和限制该技术的经验。